Digital Health Blog

Legal & Policy Insight to Empower the Evolution of Health Care

  1. CMS Releases Super Intelligence Roadmap

    The Centers for Medicare and Medicaid Services (CMS) has released a new clinical super intelligence (SI) roadmap, how the Administration is now referring to Artificial Intelligence (AI), outlining a long-term strategy to integrate the technology into care delivery and adjust payment models to support greater adoption. The framework calls for federal-state partnerships on AI sandbox programs, the development of alternative payment models, and the creation of a federal clinical SI liability framework designed to support innovation while managing risk. CMS also signals plans to expand the Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model into primary care, reflecting the agency’s broader interest in outcomes-based reimbursement. Notably, CMS envisions a future in which clinical SI evolves from a clinician support tool into a more direct provider of patient care, though the agency does not identify a timeline for that transition. Further guidance and regulation are likely as the agency continues to refine its approach based upon its guiding principles that are focused on safety, adoption, patient control, affordability, and market access. Further analysis from the firm can be found here.

  2. HHS Finalizes HIPAA Privacy Rule Changes

    The Department of Health and Human Services (HHS) Office for Civil Rights (OCR) has finalized its long-awaited rule, HIPAA Privacy Rule: Changes to Support Coordinated Care and Individual Engagement and Reduce Regulatory Burdens, which amends 45 CFR Parts 160 and 164. The rule finalizes, with modifications, proposals first issued in 2021. Among other changes, the rule shortens the deadline for responding to patient access requests, defines when access must be free, expands express permissions for care coordination disclosures, and simplifies Notice of Privacy Practices (NPP) requirements. OCR also discusses at length how HIPAA’s access obligations interact with the federal information blocking regulations. These changes are relevant to covered entities, business associates, and digital health companies that support access workflows, patient-facing apps, and data exchange. Further analysis from the firm can be found here.

  3. AMA Launches AI Campaign and Expert Network

    The American Medical Association (AMA) has launched a new public awareness campaign, “Did you ask your doctor?”, encouraging patients to consult their physician before acting on medical advice found online. The initiative addresses the growing influence and risks posed by social media health content, reliance on AI chatbots for medical advice, and the amplification of misinformation through AI tools. Through the campaign, the AMA aims to strengthen the patient-physician relationship and promote informed, evidence-based healthcare decisions. In addition, the organization is building a Digital health and AI Expert Network, and encouraging participation from physicians and medical students whose expertise, experiences, and perspectives can inform the AMA’s work in digital health and AI.

  4. AMA and FSMB Releases Paper on AI and the Practice of Medicine

    The American Medical Association (AMA) and the Federation of State Medical Boards (FSMB) have released proceedings from their recent summit on accountability and responsibility for artificial intelligence in medicine, bringing together physicians, regulators, policymakers, and technology experts to address the safe and ethical integration of AI into healthcare. The report outlines key considerations for governance, physician oversight, transparency, patient safety, and professional accountability as AI tools become more widely adopted in clinical practice. The organizations emphasized that AI should support, not replace, physician judgment and highlighted the need for clear frameworks to ensure patient trust and high-quality care. Elements of this report may influence the continued development of guidance from the FSMB’s Workgroup on the Regulation of AI in the Practice of Medicine, expected in early 2027.

  5. Physician Fee Schedule Rule Includes Remote Monitoring Provisions

    The CY 2027 Medicare Physician Fee Schedule Final Rule includes several provisions affecting remote physiologic monitoring (RPM) and remote therapeutic monitoring (RTM). CMS finalized policies requiring RTM services to be furnished to established patients and generally requiring a separately reportable initiating visit when RPM or RTM services begin. CMS also finalized updates to the valuation of these services under the PFS. However, CMS delayed until January 1, 2029, the requirement that clinical staff furnishing RPM or RTM services be employed by the billing practice rather than contractors.

  6. CMS Establishes Software as a Medicare Service Framework

    CMS’s Outpatient Prospective Payment System (OPPS) final rule establishes a new Medicare payment framework for Software as a Medical Service (SaMS), recognizing the growing role of standalone clinical decision support and algorithm-driven technologies in patient care. The rule creates a dedicated OPPS status indicator for SaMS services, assigns these technologies to New Technology Ambulatory Payment Classifications (APCs), and maintains current payment levels while CMS develops a more permanent reimbursement methodology. CMS also shifts certain algorithmic analyses performed on laboratory test data from the Clinical Laboratory Fee Schedule into the OPPS, signaling a broader effort to modernize Medicare payment policy for digital health technologies and support the integration of innovative software tools into outpatient care settings.

  7. HHS Finalizes HTI-5 Deregulatory Rule

    On October 26, 2026, the Department of Health and Human Services (HHS) and the Office of the National Coordinator for Health Information Technology (ONC) released the long-awaited HTI-5 Final Rule. The rule implements updates to the health information technology certification criteria in a significantly narrower form than proposed, removing 14 certification criteria and revising 7 out of 60 total criteria rather than the 34 proposed for elimination by ONC at the end of 2025. Among the changes, the rule eliminates annual Real World Testing plan submissions, reduces Insights Condition reporting metrics, and removes “model card” source attribute transparency and risk management mandates under the Decision Support Interventions criterion. On the removal of transparency requirements for decision support interventions, ONC took this action despite a “large majority of commenters” disfavoring the proposal, citing to concerns about it leading to a shift in “evaluation, governance, and liability burdens to providers and health systems and undermine patient safety, clinician trust, and the ability to evaluate bias, performance, and appropriateness.” The agency did elect to retain all privacy and security certification criteria, Quality Management System standards, and Accessibility-centered Design requirements in response to public feedback, however, while extending the deadline for removing document-based transitions of care requirements to January 1, 2030, to provide stakeholders a gradual transition toward Fast Healthcare Interoperability Resources-based API data exchange. Notably as well, the information blocking proposals were all omitted from this release and remain under consideration for future rulemaking (likely in a forthcoming HTI-6).

    For more information about ONC’s finalized changes and regulatory timelines, review the ONC HTI-5 Final Rule Overview Fact Sheet and the HTI-5 Criteria Removals and Revisions Fact Sheet. In addition, ONC will hold an information session on the Final Rule on October 29, for which you can register here.

  8. Federal Bill Targets Corporate Influence in Health Care and PC-MSO Structures

    On September 16, the Stop Corporate Takeovers of Physicians Act was introduced by Sens. Elizabeth Warren, Ron Wyden, and Jeff Merkley, along with Reps. Val Hoyle, Suhas Subramanyam, and Alexandria Ocasio-Cortez. The legislation largely mirrors Oregon’s SB 951, which took effect earlier this year, and comes amid growing state and federal efforts to address corporate involvement in health care, including increased scrutiny of physician practice management and PC-MSO arrangements in California.

    Key Provisions of the proposed federal legislation include:

    • Prohibition on private equity firms, insurers, and other for-profit corporations from owning or controlling medical practices.
    • Closing the longstanding “friendly physician” model by restricting MSO arrangements that effectively allow investors to control physician practices despite state CPOM prohibitions.
    • Bans on MSOs exercising control over core business, operational, and clinical functions, including hiring and firing decisions, physician compensation, scheduling, revenue targets, contracting, and billing practices.
    • Physician owners must be licensed and actively engaged in the delivery of care within the state where the practice operates.
    • Physician must retain authority over clinical judgement and a prohibition on contractual provisions, including non-compete, non-disclosure, and non-disparagement agreements are banned.

    For health care investors, MSOs, physician groups, and health systems, the legislation is another signal that scrutiny of management and ownership structures is likely to intensify. Although prior efforts to implement similar legislation in the states have failed, this bill may cause more states may look to reintroduce similar legislation in 2027 legislative sessions.

    For a deeper analysis of the proposal and its practical implications for providers and MSOs, see the HLB Digital Health Team’s article, Federal Bill Seeks to Outlaw the Friendly PC/MSO Model Nationwide, but State Enforcement Is the Real Near-Term Risk.

  9. California Enacts New AI and Consumer Privacy Laws

    California Gov. Gavin Newsom has signed several bills aimed at regulating the use of artificial intelligence in health care settings. Collectively, the new laws reinforce and clarify existing principles requiring meaningful human oversight of AI tools that influence clinical decision-making. Among them, AB 1979 prohibits providers from using an AI-enabled tool, system, or device to independently perform clinical functions that state law reserves for licensed professionals or from directing unlicensed personnel to perform those functions. The bill also emphasizes that licensed providers must retain independent professional judgment when evaluating and acting on AI-generated recommendations in patient care.

    AB 2575 protects the ability of health care professionals to override AI-generated recommendations and prohibits developers and deployers from using a clinician’s decision to override an AI system as a defense in litigation alleging harm caused by the system’s output. SB 503 requires developers to take reasonable steps to identify, assess, and mitigate foreseeable risks of bias arising from the use of AI-assisted clinical decision support systems.

    The legislature also approved , The Wellness for Oversight and Psychological Resources Act, SB 903, was signed into law and prohibits the provision or marketing of psychotherapy services through companion chatbots, including representations that a chatbot is a therapist or provides therapy. The bill, which parallels legislation first of its kind legislation which enacted in Illinois and replicated elsewhere, requires review and oversight by licensed professionals when AI is used for certain mental health-related functions, including therapeutic decision-making, triage, screening, and the detection or assessment of an individual’s mental or emotional state.

    Also enacted are two notable amendments to the California Consumer Privacy Act (CCPA). AB 1542 prohibits businesses from selling or sharing a consumer’s sensitive personal information with third parties unless the consumer intentionally discloses the information or intentionally interacts with the third party. SB 923 expands the CCPA’s deletion right to cover all information a business has collected about a consumer and requires businesses that operate exclusively online to provide a dedicated online mechanism, such as a webform or portal, for consumer requests in addition to an email address. Together, these measures strengthen consumer control over personal information and expand businesses’ compliance obligations under the CCPA.

  10. Comments on FDA’s Discussion Paper on GenAI in Health Care Due October 19

    The comment period remains open for the Food and Drug Administration’s discussion paper on regulatory considerations for generative artificial intelligence (GenAI)-enabled medical devices. The paper outlines a potential framework designed to address the unique capabilities and risks associated with GenAI technologies, including a two-axis risk assessment model and a premarket evaluation approach based on “competency assessment.” Under this approach, GenAI-enabled devices would be evaluated through a combination of non-clinical benchmarking and clinical confirmation to demonstrate that they perform as intended before reaching patients. The discussion paper also explores risk-based postmarket monitoring strategies and identifies key regulatory considerations for foundation models and increasingly autonomous agentic AI systems. Collectively, the proposals offer an early look at how the FDA may approach oversight of the next generation of AI-enabled medicine. Comments are due by October 19, 2026.